Volitionrx (VNRX) EBITDA (2012 - 2025)

Volitionrx has reported EBITDA for 10 years, with the latest figure at -$6.2 million in Q4 2025.

• For the quarter ending Q4 2025, EBITDA fell 10.05% year-over-year to -$6.2 million; the trailing twelve-month figure through Dec 2025 stood at -$24.2 million (up 10.81% YoY), and the FY2025 full-year result was -$24.2 million, up 10.81% from the prior year.
• EBITDA for Q4 2025 stood at -$6.2 million, down from -$5.4 million in the prior quarter.
• The five-year high for EBITDA was -$5.4 million in Q3 2025, with the low at -$9.5 million in Q2 2023.
• Historically, EBITDA has averaged -$7.3 million across 5 years, with a median of -$7.5 million in 2022.
• Annual changes were most pronounced in 2021 — EBITDA plunged 67.89% — and 2024, when it surged 36.2%.
• Volitionrx's EBITDA stood at -$8.8 million in 2021, then advanced by 15.49% to -$7.4 million in 2022, then retreated by 18.46% to -$8.8 million in 2023, then surged by 36.2% to -$5.6 million in 2024, then slipped by 10.05% to -$6.2 million in 2025.
• The last three EBITDA figures came in at -$6.2 million (Q4 2025), -$5.4 million (Q3 2025), and -$6.9 million (Q2 2025), per Business Quant data.